IMI Graham Hughes

Innovative Medicines Initiative Graham Hughes UK National Contact Point Health "By joining the best academic teams with high-level industry scientists, IMI is building the research capacity needed to cure the major diseases of our time." Michel Goldman, IMI Executive Director

Innovative Medicines Initiative

IMI in the Health Theme Activity 1: Biotechnology, generic tools & technologies for health Activity 2: Translating research for human health Activity 3: Optimising the delivery of health care cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender -related health issues Activity 4: Support actions & response to policy needs The Innovative Medicines Initiative

Why is IMI needed?

What are the Expected Results?
To modernise the development process of medicines;
To drive the development of innovative medicines with a high level of safety and efficacy, for millions of patients;
To generate more and better quality jobs for scientists , reversing the European brain drain;
To enhance European expertise and know-how in new technologies to attract pharmaceutical R&D investment to Europe;
To create a stronger competitive advantage for smaller companies (SMEs, spin-offs and start-ups) and public organisations by collaborating with a multitude of stakeholders.

How to Achieve Results
Support “pre-competitive pharmaceutical research and development ” – accelerate the development of safer and more effective medicines for patients
Modernization of the drug development process , via new approaches, methods and technologies, better use of research results and data and more skilled staff
Foster collaboration between stakeholders , e.g industry, academia, patient organisations, public authorities (inc regulators) , clinical centres etc
Addresses the challenges in the development process of drugs rather than aiming to deliver new medicine s

How is it funded?
EFPIA members fully fund their own participation and provide R&D resources such as staff, laboratories, materials and clinical research .
EU funds exclusively public organisations or nonprofit organisations and small and medium-sized enterprises (SMEs).

IMI Governance

IMI Research Agenda

IMI Projects: Key facts
Open and competitive calls with a peer review process by independent experts
Average project size €15 - 20 million
Average consortium size in the range of:
9 – 16 pharmaceutical companies
9 – 37 academic, SME, regulatory, patient organisations
EU funding to academic, SME and other partners is
75% of total eligible research costs
100% of total eligible management and training costs
Total eligible costs include direct eligible costs plus 20% overheads

IMI Research Consortium

IMI Call Process

1 st Call (2008) 15 Projects 395 teams 24 SMEs 11 patient organisations EU Budget = €281 Million
Pillars :
Drug Safety
Education and Training
Thematic Areas
Neurosciences
Diabetes
Lung Disease
UK SMEs CXR Biosciences Psynova Neurotech Synairgen Reasearch Choice Pharma

2 nd Call (2009)
Projects start March 2011
8 Projects
EFPIA teams
103 Academic teams
23 SMEs
2 patient organisations
EU Budget = €172 Million
Pillars :
Drug Efficacy
Knowledge Management
Thematic Areas
Cancer
Rheumatoid Arthritis
Infectious Disease
UK SMEs Cyprotex Discovery Mango Business Solutions Simcyp Ltd Assero Ltd Academic Concept Knowledge Ltd

3 rd Call (2010) Launched 22 Oct 2010 EoI Deadline 18 Jan 2011 Evaluations March/April EU Budget = €114 Million
Pillars :
Drug Safety
Drug efficacy
Education and Training
Thematic Areas
Inflammatory Disease
Neurological Disease
Infectious Disease
Diabetes

4 th Call

Launch Date 17 th June 2011

Support
http://www.imi.europa.eu

IMI Graham Hughes

by CK Group on May 23, 2011

Accessibility

Categories

Tags

Upload Details

Usage Rights

1 Embed 48

Statistics

IMI Graham Hughes — Presentation Transcript